BiomeDx presents new insights about the intestinal microbiome and response to immunotherapy at CIMT 2023
MAINZ, May 5th:
CIMT represents Europe’s Cancer Immunotherapy Meeting. The 20th edition of this annual conference took place in Mainz, Germany, between the 3-5th May 2023 (https://www.meeting.cimt.eu).
During the poster session, BiomeDx’s business development team presented results from a preliminary study involving the application of BiomeOne, the recently released stool test to predict patient response to immunotherapy (more about BiomeOne), on a large database of human microbiomes to investigate the prevalence of responders in an European population. The study revealed a relatively high prevalence of responders, and showed an impact of the use of antibiotics, among other factors, in the response rate.
Biome Diagnostics GmbH (BiomeDx®) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.
Presented poster: Application of the microbiome-based prediction test BiomeOne quantifies antibiotic, geographical and health-related effects on response to cancer immunotherapy in a large European cohort